Randomized controlled multicenter trial on the effectiveness of the collagen hemostat Sangustop® compared with a carrier-bound fibrin sealant during liver resection (ESSCALIVER study, NCT00918619)

C Moench, A L Mihaljevic, V Hermanutz, W E Thasler, K Suna, M K Diener, D Seehofer, H J Mischinger, B Jansen-Winkeln, H P Knaebel, W O Bechstein, C Moench, A L Mihaljevic, V Hermanutz, W E Thasler, K Suna, M K Diener, D Seehofer, H J Mischinger, B Jansen-Winkeln, H P Knaebel, W O Bechstein

Abstract

Background: Despite improvements in liver surgery over the past decades, hemostasis during hepatic resections remains challenging. This multicenter randomized study compares the hemostatic effect of a collagen hemostat vs. a carrier-bound fibrin sealant after hepatic resection.

Methods: Patients scheduled for elective liver resection were randomized intraoperatively to receive either the collagen hemostat (COLL) or the carrier-bound fibrin sealant (CBFS) for secondary hemostasis. The primary endpoint was the proportion of patients with hemostasis after 3 min. Secondary parameters were the proportions of patients with hemostasis after 5 and 10 min, the total time to hemostasis, and the complication rates during a 3 months follow-up period.

Results: A total of 128 patients were included. In the COLL group, 53 out of 61 patients (86.9 %) achieved complete hemostasis within 3 min after application of the hemostat compared to 52 out of 65 patients (80.0 %) in the CBFS group. The 95 % confidence interval for this difference [-6.0 %, 19.8 %] does not include the lower noninferiority margin (-10 %). Thus, the COLL treatment can be regarded as noninferior to the comparator. The proportions of patients with hemostasis after 3, 5, and 10 min were not significantly different between the two study arms. Postoperative mortality and morbidity were similar in both treatment groups.

Conclusion: The collagen hemostat is as effective as the carrier-bound fibrin sealant in obtaining secondary hemostasis during liver resection with a comparable complication rate.

Trial registration: ClinicalTrials.gov NCT00918619.

Figures

Fig. 1
Fig. 1
CONSORT flow chart
Fig. 2
Fig. 2
Kaplan–Meier curves for the time to hemostasis for COLL (dashed line) and CBFS

References

    1. Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD, Pawlik TM. National trends in surgical procedures for hepatocellular carcinoma: 1998–2008. Cancer. 2012;118(7):1838–1844. doi: 10.1002/cncr.26501.
    1. Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non-resectable) limit? J Surg Oncol. 2010;102(8):922–931. doi: 10.1002/jso.21727.
    1. Dimick JB, Wainess RM, Cowan JA, Upchurch GR, Jr, Knol JA, Colletti LM. National trends in the use and outcomes of hepatic resection. J Am Coll Surg. 2004;199(1):31–38. doi: 10.1016/j.jamcollsurg.2004.03.005.
    1. McColl RJ, You X, Ghali WA, Kaplan G, Myers R, Dixon E. Recent trends of hepatic resection in Canada: 1995–2004. J Gastrointest Surg Nov. 2008;12(11):1839–1846. doi: 10.1007/s11605-008-0679-4.
    1. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection. Ann Surg. 2002;236(4):397–407. doi: 10.1097/00000658-200210000-00001.
    1. Asiyanbola B, Chang D, Gleisner AL, Nathan H, Choti MA, Schulick RD, Pawlik TM. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg. 2008;12(5):842–851. doi: 10.1007/s11605-008-0494-y.
    1. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–1016. doi: 10.1016/S0140-6736(08)60455-9.
    1. Ammori JB, Pelletier SJ, Lynch R, Cohn J, Ads Y, Campbell DA, Englesbe MJ. Incremental costs of post-liver transplantation complications. J Am Coll Surg. 2008;206(1):89–95. doi: 10.1016/j.jamcollsurg.2007.06.292.
    1. Brown RS, Jr, Ascher NL, Lake JR, Emond JC, Bacchetti P, Randall HB, Roberts JP. The impact of surgical complications after liver transplantation on resource utilization. Arch Surg. 1997;132(10):1098–1103. doi: 10.1001/archsurg.1997.01430340052008.
    1. Bechstein WO, Neuhaus P. Bleeding problems in liver surgery and liver transplantation. Chirurg. 2000;71(4):363–368. doi: 10.1007/s001040051066.
    1. Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. Br J Surg. 2008;95(10):1197–1225. doi: 10.1002/bjs.6357.
    1. Jackson MR. New and potential uses of fibrin sealants as an adjunct to surgical hemostasis. Am J Surg. 2001;182(2 Suppl):36S–39S. doi: 10.1016/S0002-9610(01)00775-9.
    1. Kohno H, Nagasue N, Chang YC, Taniura H, Yamanoi A, Nakamura T. Comparison of topical hemostatic agents in elective hepatic resection: a clinical prospective randomized trial. World J Surg. 1992;16(5):966–969. doi: 10.1007/BF02067005.
    1. Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, Colonna JO, 2nd, Heaton N, Mirza D, Adams R, Rees M, Lloyd D. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg. 2004;139(11):1148–1154. doi: 10.1001/archsurg.139.11.1148.
    1. Chapman WC, Clavien PA, Fung J, Khanna A, Bonham A. Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg. 2000;135(10):1200–1204. doi: 10.1001/archsurg.135.10.1200.
    1. Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger H-J, Gassel H-J, Rokkjaer M, Schauer R, Larsen PN, Tetens V, Büchler MW. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149(1):48–55. doi: 10.1016/j.surg.2010.02.008.
    1. Frilling A, Stavrou GA, Mischinger H-J, de Hemptinne B, Rokkjaer M, Klempnauer J, Thörne A, Gloor B, Beckebaum S, Ghaffar MFA, Broelsch CE. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390(2):114–120. doi: 10.1007/s00423-005-0543-x.
    1. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, Fischer C, Garden OJ. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford) 2013;15(1):61–70. doi: 10.1111/j.1477-2574.2012.00583.x.
    1. Moench C, Bechstein WO, Hermanutz V, Hoexter G, Knaebel H-P. Comparison of the collagen haemostat Sangustop® versus a carrier-bound fibrin sealant during liver resection; ESSCALIVER-study. Trials. 2010;11:109. doi: 10.1186/1745-6215-11-109.
    1. Takács I, Wegmann J, Horváth S, Ferencz A, Ferencz S, Jávor S, Odermatt E, Roth E, Weber G. Efficacy of different hemostatic devices for severe liver bleeding: a randomized controlled animal study. Surg Innov. 2010;17(4):346–352. doi: 10.1177/1553350610384405.
    1. Shander A. Financial and clinical outcomes associated with surgical bleeding complications. Surgery. 2007;142(4 Suppl):S20–S25. doi: 10.1016/j.surg.2007.06.025.
    1. de Boer MT, Molenaar IQ, Porte RJ. Impact of blood loss on outcome after liver resection. Dig Surg. 2007;24(4):259–264. doi: 10.1159/000103656.
    1. Yang T, Zhang J, Lu J-H, Yang G-S, Wu M-C, Yu W-F. Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg. 2011;35(9):2073–2082. doi: 10.1007/s00268-011-1161-0.
    1. Arikawa T, Kurokawa T, Ohwa Y, Ito N, Kotake K, Nagata H, Miyachi M, Suzumura K, Nonami T. Risk factors for surgical site infection after hepatectomy for hepatocellular carcinoma. Hepatogastroenterol. 2011;58(105):143–146.
    1. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D’Angelica MI, Blumgart LH, Dematteo RP. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249(4):617–623. doi: 10.1097/SLA.0b013e31819ed22f.
    1. Gugenheim J, Bredt LC, Iannelli A. A randomized controlled trial comparing fibrin glue and PlasmaJet on the raw surface of the liver after hepatic resection. Hepatogastroenterol. 2011;58(107–108):922–925.
    1. Garancini M, Gianotti L, Mattavelli I, Romano F, Degrate L, Caprotti R, Nespoli A, Uggeri F. Bipolar vessel sealing system vs. clamp crushing technique for liver parenchyma transection. Hepatogastroenterol. 2011;58(105):127–132.
    1. FDA (2013) Guidance for industry. Efficacy studies to support marketing of fibrin sealant products manufactured for commercial use. . Accessed 30 January 2013

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel